Egetis Therapeutics AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was SEK 5.1 million compared to SEK 6.2 million a year ago. Revenue was SEK 5.2 million compared to SEK 6.2 million a year ago. Net loss was SEK 53.9 million compared to SEK 18.8 million a year ago. Basic loss per share from continuing operations was SEK 0.3 compared to SEK 0.1 a year ago. Diluted loss per share from continuing operations was SEK 0.3 compared to SEK 0.1 a year ago.
For the nine months, sales was SEK 16.9 million compared to SEK 35 million a year ago. Revenue was SEK 17 million compared to SEK 35 million a year ago. Net loss was SEK 115.9 million compared to SEK 72.5 million a year ago. Basic loss per share from continuing operations was SEK 0.6 compared to SEK 0.4 a year ago. Diluted loss per share from continuing operations was SEK 0.6 compared to SEK 0.4 a year ago.